DMK Pharmaceuticals Corporation

DMKPQ

US00547W3079

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:53:07 2024-04-26 pm EDT			5-day change	1st Jan Change
0.035 ^USD	-2.78%		-30.42%	-95.00%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

DMK Pharmaceuticals Corporation Announces Board Appointments

January 31, 2024 at 05:18 pm EST

DMK Pharmaceuticals Corporation announced that at its meeting of stockholders held on January 25, 2024 elected Ebrahim Versi, M.D., Ph.D. and Jannine Versi to its board of directors.

Latest news about DMK Pharmaceuticals Corporation

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Bidding Procedure Approved for DMK Pharmaceuticals Corporation	Apr. 04	CI
Motion for Asset Sale Filed by DMK Pharmaceuticals Corporation	Mar. 21	CI
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index	Feb. 07	CI
Motion for Joint Administration Approved for DMK Pharmaceuticals Corporation	Feb. 06	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index	Feb. 05	CI
Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation	Feb. 02	CI
DMK Pharmaceuticals Corporation Filed for Bankruptcy	Feb. 02	CI
DMK Pharmaceuticals Corporation Announces Board Appointments	Jan. 31	CI
Maxim Starts DMK Pharmaceuticals With Buy Rating, $1.50 Price Target	Dec. 07	MT
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI	Nov. 28	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) added to NASDAQ Composite Index	Nov. 20	CI
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index	Nov. 20	CI
Earnings Flash (DMK) DMK PHARMACEUTICALS CORPORATION Reports Q3 Revenue $9,062	Nov. 14	MT
DMK Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
DMK Pharmaceuticals Corporation Announces CFO Changes	23-10-19	CI
DMK Pharmaceuticals Corporation Announces Executive Changes	23-10-19	CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals	23-10-12	CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals	23-10-02	CI
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals	23-09-07	MT
Adamis Pharmaceuticals Corporation has Changed its Name to DMK Pharmaceuticals Corporation	23-09-06	CI
Earnings Flash (ADMP) ADAMIS PHARMACEUTICALS CORPORATION Posts Q2 Revenue $6,945	23-08-21	MT
Adamis Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Sector Update: Health Care Stocks Slipping Late Friday	23-08-04	MT

Chart DMK Pharmaceuticals Corporation

Duration

Period

More charts

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
DMK PHARMACEUTICALS CORPORATION	-95.00%	353K
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+26.93%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+14.15%	231B
NOVARTIS AG	+5.02%	200B
ROCHE HOLDING AG	-9.33%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals